New Immunotherapy Cancer Treatment Empliciti (Elotuzumab) For Multiple Myeloma

Empliciti (Elotuzumab) is an FDA approved immunotherapy treatment for multiple myeloma cancer. Medical oncologist Dr. Stephen Lemon talks about how this new cancer drug treatment works as well as what types of side effects it may cause.

Empliciti is developed by Bristol-Myers Squibb. Dr. Stephen Lemon is a medical oncologist and is not affiliated with Bristol-Myers Squibb.

Click on the buttons below to view more videos that we have produced

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on email
Email